Femasys Inc. (Nasdaq: FEMY) is a biomedical company focused on expanding access to women’s reproductive healthcare. Its solutions are designed for use in OB/GYN offices, helping clinicians provide fertility care and permanent birth control without requiring patients to begin with a specialist referral. The company’s fertility portfolio includes FemaSeed, an in-office, first-line insemination treatment, and diagnostic products such as FemVue and FemHSG. Femasys also offers fertility diagnostic tools for women and men, supporting care from assessment through treatment.

For permanent contraception, FemBloc is a minimally invasive, non-surgical approach that leaves no implant behind. It is approved in Europe and select other countries and is enrolling in a final pivotal trial in the United States. Femasys is seeking qualified partners to expand its availability internationally. The company’s broader portfolio also includes FemCerv. By developing products intended to integrate into existing clinical practice, Femasys aims to give OB/GYNs more options for reproductive care and help patients access earlier, more affordable fertility treatment and alternatives to surgical contraception.